Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum

Hong Kong, Oct 2, 2026 – (ACN Newswire) – Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY(R) (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY(R) is expected to begin in 2027…
Read More